Managers / Q3 2019 · view latest →
ISZO CAPITAL MANAGEMENT LP
CIK 0001607925 · 590 MADISON AVENUE, 21ST FLOOR, NEW YORK, NY, 10022 · 646-775-4394
Summary
Iszo Capital Management LP reported $76M in U.S.-listed holdings across 4 positions for Q3 2019.
The portfolio is heavily concentrated: Nam Tai Ppty alone accounts for 45.5% of reported value.
Compared with Q2 2019, the fund opened 2 new positions and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 54.0% · $41M
- Other · 46.0% · $35M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| XPELXPEL INC | NEW | +1.42M | 1.42M | +$17M | $17M |
| TOCAGEN INC | NEW | +565.9K | 565.9K | +$375,000 | $375,000 |
| AVID BIOSERVICES INC | TRIMMED | −243.4K | 4.53M | −$3M | $24M |
| NAM TAI PPTY INC | HELD | +700 | 3.82M | −$3M | $34M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | NAM TAI PPTY INC | SHS | 45.47% | $34M | 3.82M |
| 2 | AVID BIOSERVICES INC | COM | 31.80% | $24M | 4.53M |
| 3 | XPELXPEL INChistory → | COM | 22.23% | $17M | 1.42M |
| 4 | TOCAGEN INC | COM | 0.50% | $375,000 | 565.9K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q4 2023 | $2M | 1 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $2M | 3 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $18M | 3 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $19M | 10 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $7M | 7 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $58M | 6 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $64M | 6 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $84M | 5 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $190M | 7 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $227M | 7 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $275M | 8 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $212M | 5 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $96M | 6 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $74M | 5 | Nov 17, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2020 | $57M | 10 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $65M | 10 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $69M | 3 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $76M | 4 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $64M | 2 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $61M | 5 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $92M | 5 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.